摘要
目的探讨超敏C反应蛋白(hs-CRP)及B型钠尿肽(BNP)在慢性阻塞性肺病急性加重期(AECOPD)并肺心病患者中水平变化及临床意义。方法测定80例AECOPD并肺心病患者hs-CRP及BNP水平,并对患者按照美国纽约心脏病协会(NYHA)分级方案对心功能程度进行分级。同时测定40例健康体检患者hs-CRP及BNP水平。结果 AECOPD并肺心病患者hs-CRP及BNP与健康对照组比较具有统计学差异(P<0.05),AECOPD并肺心病患者NYHA心功能Ⅰ级到Ⅳ级hs-CRP与BNP浓度比较均有统计学意义(P<0.05),相关性分析显示hs-CRP及BNP与心衰程度呈正相关(r=0.415,r=0.812,P<0.05)。结论 AECOPD并肺心病患者血清hs-CRP及BNP升高,提示机体存在感染及心肌受损、心功能衰竭。联合检测CRP和BNP可以作为评价AECOPD并肺心病的预后指标。
Objective To investigate the changes of serum hs-CRP and BNP levels and their clinical significances in patients with AECOPD and chronic pulmonary heart disease.Methods Serum hs-CRP and BNP levels were measured in 80 patients with AECOPD and chronic pulmonary heart disease,and 40 healthy subjects （controls）. The heart function was classified according to the NYHA criteria. Results Serum hs-CRP and BNP levels of patients with AECOPD and chronic pulmonary heart disease were higher than those in healthy controls（P〈0. 05）. The concentrations of plasma BNP and hs-CRP increased gradually with more severe symptoms（NYHA I -IV）, and were positively correlated with NYHA class （r=0.415, r=0.812, P〈0.05） .Conclusion Combined detection of serum hs-CRP and BNP can provide reliable indicators for prevention and treatment of AECOPD and chronic pulmonary disease.
出处
《云南医药》
CAS
2012年第5期427-429,共3页
Medicine and Pharmacy of Yunnan
